The safety of progestogen in the prevention of preterm birth: Meta-analysis of neonatal mortality

Ki Hoon Ahn, Na Young Bae, Soon Cheol Hong, Ji Sung Lee, Eun Hee Lee, Hee Jung Jee, Geum-Joon Cho, Min Jeong Oh, Hai Joong Kim

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

The safety of preventive progestogen therapy for preterm birth remains to be established. This meta-analysis aimed to evaluate the effects of preventive progestogen therapy on neonatal mortality. Randomized controlled trials (RCTs) on the preventive use of progestogen therapy, published between October 1971 and November 2015, were identified by searching MEDLINE/PubMed, EMBASE, Scopus, ClinicalTrials.gov, Cochrane Library databases, CINAHL, POPLINE, and LILACS using "progesterone" and "preterm birth" as key terms. We conducted separate analyses according to the type of progestogen administered and plurality of the pregnancy. Twenty-two RCTs provided data on 11,188 neonates. Preventive progestogen treatment in women with a history of preterm birth or short cervical length was not associated with increased risk of neonatal death compared to placebo in all analyzed progestogen types and pregnancy conditions. The pooled relative risks (95% confidence interval) of neonatal mortality were 0.69 (0.31-1.54) for vaginal progestogen in singleton pregnancies, 0.6 (0.33-1.09) for intramuscular progestogen in singleton pregnancies, 0.96 (0.51-1.8) for vaginal progestogen in multiple pregnancies, and 0.96 (0.49-1.9) for intramuscular progestogen in multiple pregnancies. The results of this meta-analysis suggest that administration of preventive progestogen treatment to women at risk for preterm birth does not appear to negatively affect neonatal mortality in single or multiple pregnancies regardless of the route of administration.

Original languageEnglish
Pages (from-to)11-20
Number of pages10
JournalJournal of Perinatal Medicine
Volume45
Issue number1
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Premature Birth
Infant Mortality
Progestins
Meta-Analysis
Safety
Multiple Pregnancy
Pregnancy
Randomized Controlled Trials
Therapeutics
PubMed
MEDLINE
Libraries
Progesterone
Placebos
Newborn Infant
Databases
Confidence Intervals

Keywords

  • Neonatal death
  • preterm birth
  • progestogen

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynaecology

Cite this

The safety of progestogen in the prevention of preterm birth : Meta-analysis of neonatal mortality. / Ahn, Ki Hoon; Bae, Na Young; Hong, Soon Cheol; Lee, Ji Sung; Lee, Eun Hee; Jee, Hee Jung; Cho, Geum-Joon; Oh, Min Jeong; Kim, Hai Joong.

In: Journal of Perinatal Medicine, Vol. 45, No. 1, 01.01.2017, p. 11-20.

Research output: Contribution to journalReview article

@article{0968eae9da694fd88aed19f94e84805f,
title = "The safety of progestogen in the prevention of preterm birth: Meta-analysis of neonatal mortality",
abstract = "The safety of preventive progestogen therapy for preterm birth remains to be established. This meta-analysis aimed to evaluate the effects of preventive progestogen therapy on neonatal mortality. Randomized controlled trials (RCTs) on the preventive use of progestogen therapy, published between October 1971 and November 2015, were identified by searching MEDLINE/PubMed, EMBASE, Scopus, ClinicalTrials.gov, Cochrane Library databases, CINAHL, POPLINE, and LILACS using {"}progesterone{"} and {"}preterm birth{"} as key terms. We conducted separate analyses according to the type of progestogen administered and plurality of the pregnancy. Twenty-two RCTs provided data on 11,188 neonates. Preventive progestogen treatment in women with a history of preterm birth or short cervical length was not associated with increased risk of neonatal death compared to placebo in all analyzed progestogen types and pregnancy conditions. The pooled relative risks (95{\%} confidence interval) of neonatal mortality were 0.69 (0.31-1.54) for vaginal progestogen in singleton pregnancies, 0.6 (0.33-1.09) for intramuscular progestogen in singleton pregnancies, 0.96 (0.51-1.8) for vaginal progestogen in multiple pregnancies, and 0.96 (0.49-1.9) for intramuscular progestogen in multiple pregnancies. The results of this meta-analysis suggest that administration of preventive progestogen treatment to women at risk for preterm birth does not appear to negatively affect neonatal mortality in single or multiple pregnancies regardless of the route of administration.",
keywords = "Neonatal death, preterm birth, progestogen",
author = "Ahn, {Ki Hoon} and Bae, {Na Young} and Hong, {Soon Cheol} and Lee, {Ji Sung} and Lee, {Eun Hee} and Jee, {Hee Jung} and Geum-Joon Cho and Oh, {Min Jeong} and Kim, {Hai Joong}",
year = "2017",
month = "1",
day = "1",
doi = "10.1515/jpm-2015-0317",
language = "English",
volume = "45",
pages = "11--20",
journal = "Journal of Perinatal Medicine",
issn = "0300-5577",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "1",

}

TY - JOUR

T1 - The safety of progestogen in the prevention of preterm birth

T2 - Meta-analysis of neonatal mortality

AU - Ahn, Ki Hoon

AU - Bae, Na Young

AU - Hong, Soon Cheol

AU - Lee, Ji Sung

AU - Lee, Eun Hee

AU - Jee, Hee Jung

AU - Cho, Geum-Joon

AU - Oh, Min Jeong

AU - Kim, Hai Joong

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The safety of preventive progestogen therapy for preterm birth remains to be established. This meta-analysis aimed to evaluate the effects of preventive progestogen therapy on neonatal mortality. Randomized controlled trials (RCTs) on the preventive use of progestogen therapy, published between October 1971 and November 2015, were identified by searching MEDLINE/PubMed, EMBASE, Scopus, ClinicalTrials.gov, Cochrane Library databases, CINAHL, POPLINE, and LILACS using "progesterone" and "preterm birth" as key terms. We conducted separate analyses according to the type of progestogen administered and plurality of the pregnancy. Twenty-two RCTs provided data on 11,188 neonates. Preventive progestogen treatment in women with a history of preterm birth or short cervical length was not associated with increased risk of neonatal death compared to placebo in all analyzed progestogen types and pregnancy conditions. The pooled relative risks (95% confidence interval) of neonatal mortality were 0.69 (0.31-1.54) for vaginal progestogen in singleton pregnancies, 0.6 (0.33-1.09) for intramuscular progestogen in singleton pregnancies, 0.96 (0.51-1.8) for vaginal progestogen in multiple pregnancies, and 0.96 (0.49-1.9) for intramuscular progestogen in multiple pregnancies. The results of this meta-analysis suggest that administration of preventive progestogen treatment to women at risk for preterm birth does not appear to negatively affect neonatal mortality in single or multiple pregnancies regardless of the route of administration.

AB - The safety of preventive progestogen therapy for preterm birth remains to be established. This meta-analysis aimed to evaluate the effects of preventive progestogen therapy on neonatal mortality. Randomized controlled trials (RCTs) on the preventive use of progestogen therapy, published between October 1971 and November 2015, were identified by searching MEDLINE/PubMed, EMBASE, Scopus, ClinicalTrials.gov, Cochrane Library databases, CINAHL, POPLINE, and LILACS using "progesterone" and "preterm birth" as key terms. We conducted separate analyses according to the type of progestogen administered and plurality of the pregnancy. Twenty-two RCTs provided data on 11,188 neonates. Preventive progestogen treatment in women with a history of preterm birth or short cervical length was not associated with increased risk of neonatal death compared to placebo in all analyzed progestogen types and pregnancy conditions. The pooled relative risks (95% confidence interval) of neonatal mortality were 0.69 (0.31-1.54) for vaginal progestogen in singleton pregnancies, 0.6 (0.33-1.09) for intramuscular progestogen in singleton pregnancies, 0.96 (0.51-1.8) for vaginal progestogen in multiple pregnancies, and 0.96 (0.49-1.9) for intramuscular progestogen in multiple pregnancies. The results of this meta-analysis suggest that administration of preventive progestogen treatment to women at risk for preterm birth does not appear to negatively affect neonatal mortality in single or multiple pregnancies regardless of the route of administration.

KW - Neonatal death

KW - preterm birth

KW - progestogen

UR - http://www.scopus.com/inward/record.url?scp=85009784380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009784380&partnerID=8YFLogxK

U2 - 10.1515/jpm-2015-0317

DO - 10.1515/jpm-2015-0317

M3 - Review article

C2 - 27124668

AN - SCOPUS:85009784380

VL - 45

SP - 11

EP - 20

JO - Journal of Perinatal Medicine

JF - Journal of Perinatal Medicine

SN - 0300-5577

IS - 1

ER -